上海医药硫酸艾沙康唑原料药上市申请获得批准

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the active pharmaceutical ingredient (API) Sulfate Isavuconazole, indicating compliance with domestic drug registration requirements and enabling market sales in China [1] Group 1: Company Developments - The approval of Sulfate Isavuconazole API signifies that the product meets the necessary regulations for drug registration in China [1] - This achievement provides valuable experience for the company in future API submissions [1] - The current approval is not expected to have a significant impact on the company's operating performance for the period [1]